Ionis to hold second quarter 2024 financial results webcast
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
Go back to Ionis to hold second quarter 2024 financial results webcast
July 22, 2024 1:06 PM EDT
Jefferies analyst Akash Tewari raised the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $77.00 (from $75.00) while maintaining a Buy rating.
The analyst comments "IONS released Angelman data this AM - overall we thought the data (albeit early) looks ok/encouraging: 1) IONS582's efficacy... More
July 22, 2024 12:04 PM EDT
Goldman Sachs analyst Salveen Richter reiterated a Sell rating and $33.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).
The analyst comments "Ahead of the 2024 Angelman Syndrome Foundation conference, IONS reported six-month Ph1/2 data on antisense oligonucleotide (ASO) ION582 in Angelman syndrome (n=11, 13 and 27 at the low, medium and high doses), where 67% of medium/high-dose patients improved vs. natural history,... More
